Personnel

The Immune Response Corporation forms new scientific advisory board for multiple sclerosis

Published in Vaccine Weekly, May 3rd, 2006

The Immune Response Corporation (IMNR.OB) announced that it has formed a scientific advisory board to provide scientific and clinical direction in its development of NeuroVax, its therapeutic product candidate for the treatment of multiple sclerosis (MS).

New data indicate that an important part of the strong disease specific immune response induced by NeuroVax is the stimulation of FOXP3+ Regulatory T-cells. This approach could play an important role in the treatment of MS and other autoimmune diseases, such as rheumatoid arthritis, psoriasis and Crohn disease

The scientific advisory board guiding the development of NeuroVax will consist of six...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry